New drugs: entecavir, ibandronate sodium, and pegaptanib sodium.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D052157:Aptamers, Nucleotide; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D000077557:Ibandronic Acid; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009841:Oligonucleotides / Q000009:adverse effects / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control
D052157:Aptamers, Nucleotide; D004164:Diphosphonates; D009841:Oligonucleotides; C495058:pegaptanib; C413685:entecavir; D006147:Guanine; D000077557:Ibandronic Acid